BioCentury | Oct 28, 2020
Deals

Out of the Arena: With $56M round, spinout Longboard to house trio of neuroscience programs

...of all three.Founded in 1997, Arena reorganized in 2016 after the commercial failure of Belviq lorcaserin...
...the class. “Lorcaserin was designed to be a next-generation fenfluramine,” he said. “LP352 is next-generation lorcaserin.”He...
BioCentury | Mar 11, 2020
Product Development

Novo’s year of obesity

...approved therapies into commercial successes. Last month, Eisai Co. Ltd. (Tokyo:4523) withdrew anti-obesity drug Belviq lorcaserin...
...the request of FDA following identification of an increased cancer risk. But even before then, Belviq...
BioCentury | Feb 14, 2020
Product Development

Feb. 13 Product Development Quick Takes: Priority Review for BMS, Seattle Genetics, Deciphera therapies; plus Roche, Ipsen, Merck, Eisai and Amgen-Pfizer

...survival. Eisai takes obesity drug off market Eisai Co. Ltd. (Tokyo:4523) withdrew anti-obesity drug Belviq lorcaserin...
...nine months ending Dec. 31, Eisai reported ¥4.6 billion ($42 million) in worldwide sales for Belviq...
...Platelet derived growth factor receptor A BioCentury Staff liso-cel, lisocabtagene maraleucel, (JCAR017) tucatinib ripretinib (DCC-2618) Keytruda, pembrolizumab (MK-3475, lambrolizumab) Belviq, lorcaserin (APD356) G-Lasta...
BioCentury | Nov 16, 2018
Company News

Arena licenses ralinepag to United, moves S1PR1 agonist to center stage

...when it announced a major restructuring in the wake of disappointing sales for weight-loss drug Belviq...
BioCentury | Nov 16, 2018
Company News

Arena licenses ralinepag to United, moves S1PR1 agonist to center stage

...when it announced a major restructuring in the wake of disappointing sales for weight-loss drug Belviq...
BioCentury | Aug 17, 2018
Clinical News

Eisai's Belviq does not increase MACE in CVOT for weight management drug

...Eisai Co. Ltd. (Tokyo:4523) said Belviq lorcaserin met the primary safety endpoint by not increasing the...
...Arena Pharmaceuticals Inc. (NASDAQ:ARNA), San Diego, Calif. Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Product: Belviq lorcaserin...
...angina, heart failure or any coronary revascularization Status: Phase IIIb/IV data Milestone: NA Jennie Walters Belviq, lorcaserin (APD356) Arena...
BioCentury | Aug 3, 2018
Company News

Eisai grants CY Biotech Greater China rights to lorcaserin

...rights to CY Biotech Co. Ltd. (Taipei, Taiwan) to develop and market obesity drug lorcaserin (APD356...
...well as an option to market lorcaserin in Hong Kong and Macao. It will supply lorcaserin...
...Co. Ltd. (Tokyo:4523), Tokyo, Japan CY Biotech Co. Ltd., Taipei, Taiwan Business: Endocrine/Metabolic Jennie Walters Belviq, lorcaserin (APD356) CY...
BioCentury | May 1, 2018
Distillery Therapeutics

Neurology

...Inc., Eisai Co. Ltd. and Ildong Pharmaceutical Co. Ltd. have the 5-HT2C receptor agonist Belviq lorcaserin...
BioCentury | Sep 21, 2017
Targets & Mechanisms

Appetite for GFRAL

...of the five marketed obesity therapies that target neurotransmitter systems: Arena Pharmaceuticals Inc. ’s Belviq lorcaserin...
BioCentury | Jul 21, 2017
Clinical News

Phase III CAMELLIA-TIMI CVOT for Belviq ongoing

...DMC recommended continuation of the Phase IIIb/IV CAMELLIA-TIMI 61 cardiovascular outcomes trial of Belviq lorcaserin (APD356...
...stroke and cardiovascular (CV) death. The double-blind, placebo-controlled, international trial is evaluating 10 mg oral Belviq...
...Pharmaceuticals Inc. (NASDAQ:ARNA), San Diego, Calif. Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Product: Belviq lorcaserin (APD356...
Items per page:
1 - 10 of 351